Digital Healthcare Partners (DHP), a leading Korean digital healthcare-focused investment firm, has announced a new investment in Beyond Medicine, a Korean startup developing a digital therapeutic (DTx) for the dental sector.

Beyond Medicine is currently developing Clickless, a digital therapeutic targeting temporomandibular disorder (TMD). This healthcare startup designed Clickless to deliver a non-pharmacological treatment program consisting of personalized lifestyle interventions, cognitive behavioral therapy based on pain tracking, self-guided rehabilitation exercises, and mindfulness therapy. The program is structured as a 10-minute daily regimen over six weeks.

The therapeutic efficacy of Clickless was supported by promising outcomes from an exploratory clinical trial conducted at Seoul National University Bundang Hospital. The trial showed significant improvements in pain reduction and jaw mobility, and the findings were published in a peer-reviewed SCI-level journal. Based on these results, Clickless achieved a milestone by being designated as an “Innovative Medical Device” (No. 82) by Korea’s Ministry of Food and Drug Safety (MFDS)—the first such designation for a dental digital therapeutic. The company has completed multicenter pivotal trials and has submitted an application for product approval, targeting commercial clinical deployment in the second half of 2025.

Recognizing the unique characteristics of dental clinics, where non-reimbursed treatments are common, Beyond Medicine has devised a market entry strategy tailored to this environment. The company has established a strong advisory board of leading experts in oral and maxillofacial surgery and internal oral medicine. Additionally, through participation in dental expos and seminars, Beyond Medicine has built a prescription collaboration network with over 1,000 clinics and hospitals across Korea.

Commenting on the investment, Gayoung Hong, Investment Manager at DHP, stated, “We were particularly drawn to the team’s ability to offer a precise digital solution in a field—TMD—that has seen high patient demand but few effective treatments. Their execution in clinical validation, product design, and market strategy positions them as a frontrunner in the commercialization of digital therapeutics.”

Dr. Daehyun Kim, CEO of Beyond Medicine and a graduate of Yonsei University College of Dentistry, has designed the therapeutic based on clinical experience. “The key to digital therapeutics lies not in the technology itself, but in applicability and delivery within real-world clinical settings. Clickless was developed with a sharp focus on suitability for dental practices,” he explained. “We remain committed to delivering meaningful therapeutic outcomes for both clinicians and patients.”

Looking ahead, Beyond Medicine is preparing for global market expansion, including regulatory approval from the U.S. FDA. The company is actively working on clinical strategies and partnership development, while simultaneously pursuing follow-on investments and TIPS (Tech Incubator Program for Startups) selection to solidify its leadership in the DTx sector.